ISRRT 150614
-
Upload
anne-kairenius -
Category
Documents
-
view
103 -
download
2
Transcript of ISRRT 150614
Comprehensive Cancer Center Tampere (TAMCAN)
ISRRT 15.6.2014 Anne Kairenius
Pirkanmaa Hospital District – Anne Kahiluoto2 02.05.23
Tampere University Hospital
Pirkanmaa Hospital District – Anne Kahiluoto3 02.05.23
Introduction The working group of the Ministry of Social Affairs and Health
proposes that the Finnish comprehensive cancer center comprise a national coordinating centre and five regional centres which could function in close association with existing university hospitals and the catchment areas for providing specialist care.
Financing: Initially, operations would need to be funded mainly from the state budget and would require funding from a main title of expenditure of the Ministry of Social Affairs and Health for a minimum period of three years.
The better the center is able to integrate nationally diagnostics and care with high quality research and teaching, the more significant Comprehensive Cancer Center Finland’s (FICAN) added value will be. FICAN will ensure equitable access to high quality care for cancer patients in Finland beyond 2020.
Pirkanmaa Hospital District – Anne Kahiluoto4 02.05.23
Introduction Comprehensive Cancer Center Finland (FICAN) = national
coordinating center (Helsinki) and five regional centres (Helsinki, Kuopio, Oulu, Tampere, Turku)
The cancer center will ensure a high quality treatment to Finnish cancer patients with comparable and cost-effective care transition. The number of cancer patients is increasing and the cancer treatment becomes more and more individual
Cancer diseases are becoming one of the most important chronic diseases worldwide
Pirkanmaa Hospital District – Anne Kahiluoto5 02.05.23
Introduction In Finland, one in four deaths is caused by cancer The rate of cancer is increasing every year, with the population
living longer and the aging of the baby-boom generation willtriple cancer costs from 2004 to 2020 (EUR 1.5 billion / year)
The aim is individually tailored therapies (personalized medicine)efficiently and effectively
Cost-effective cancer treatments can be developed only by integrating treatment to clinical and translational research
To achieve aims integrated care lines are needed The response to challenges has been Comprehensive Cancer
Centers, which integrate cancer treatment and research past 50 years in the US (42 centers, Europe 7)
Pirkanmaa Hospital District – Anne Kahiluoto6 02.05.23
Introduction Our multi-disciplinary treatment team consists of different types of
expertise, which addresses the patient's disease: surgery, chemotherapy, radiation therapy, pathology, genetics, imaging, palliative care, psychosocial support and rehabilitation
According to international statistics the cancer treatment results in our country are in the level of high international standard, but rapidly increasing of research and its exploitation set new requirements for the implementation of cancer treatment
By using molecular biology and cell biology methods more and more growth path errors will be found in cancers. Errors can be affected by the regulation of new drugs
Scientists may not have found cures for all forms of cancer, but researchers have discovered numerous ways to treat and manage many of the more than 200 variations of this disease
Pirkanmaa Hospital District – Anne Kahiluoto7 02.05.23
What is TAMCAN? The task is to promote cancer treatment, research and training Know-how especially in the wide-ranging prostate and breast cancer study Supports also other types of cancer research and high-quality care Phase I-II center (early-stage clinical trials are at a low level for the future) Produces research services, and develops new innovations in translational
research (forms a bridge between basic research and patient care) in cancer treatment and prevention
The aim is that every tenth patient visit should be associated to research TAMCAN organizes high-quality research training for catchment areas as
well as nationally and internationally, in conjunction with the University and the University of Applied Sciences
New drugs given to patients are research based
Pirkanmaa Hospital District – Anne Kahiluoto8 02.05.23
Operations and customers The main customer groups are: Pirkanmaa Hospital District's
municipalities and patients, the catchment areas of the central hospitals (Pirkanmaa, Lahti, Hämeenlinna, Vaasa), pharmaceutical industry, surgery, radiotherapy and diagnostic equipment manufacturers, domestic and international research community and patient organizations
Clinical cancer trials save approximately 1.5 million euros annually
Pirkanmaa Hospital District – Anne Kahiluoto9 02.05.23
Objectives TAMCAN combines:
• basic• translational• clinical• public health• scientific research and service system in cancer prevention• screening• diagnostics• treatment and rehabilitation with development.
Finland's leading cancer research center in the overall patient treatment and on the top of international level, and in other selected research areas at the good international level by the year 2020.
National Center of the Cancer education
Pirkanmaa Hospital District – Anne Kahiluoto10 02.05.23
Phase I-II trial center To investigate the first time cancerdrug effects in humans to
molecule drug absorption, distribution, metabolism, or excretion of the human body
The trials is to find treatments that are more effective in controlling cancer with fewer side effects
Small number of patients in trials The intention is to carry out research projects, which are in Finland
scientifically necessary Development of drugs that affect specific targets in the cancer cell is
important. Clinical trials validate the efficacy of these drugs To develop more effective therapy to different type of cancers
personalized medicine
Pirkanmaa Hospital District – Anne Kahiluoto11 02.05.23
Phase I-II trial center Patients are mainly from Finland, but also from Estonia and Russia New and modern specialization to medical oncology and radiation
therapy, clinical hematology and pharmacology, as well as specialized gynecological oncology
Studies can allow participants to benefit from the newest treatments for several years before they become available at a pharmacy
First in Finland Situated in oncology ward with four beds
Pirkanmaa Hospital District – Anne Kahiluoto12 02.05.23
Staff Employed by a hospital or university
Phase I-II- trialcenter hospital staff: 2 doctors, four research nurses, research coordinator, research assistant
Our medical staff have close ties to prominent hospitals and current cancer research, and we bring those breakthrough advances to our regional centers to progress the level of care
Pirkanmaa Hospital District – Anne Kahiluoto13 02.05.23
Success Factors Services that support Clinical studies can be implemented uniformly
with the other national centers and international centers
Pirkanmaa Hospital District – Anne Kahiluoto14 02.05.23
What are the biggest barriers to moving cancer research forward faster?
By far our greatest barrier is the lack of money and resources going into research. Many research ideas or grants that should be funded do not get funded due to lack of money.
A second major issue is the lack of adults participating in cancer clinical treatment trials.
Pirkanmaa Hospital District – Anne Kahiluoto15 02.05.23
Organization The organization of TAMCAN consists of board of TAMCAN,
scientific expert group and board of directors all working in Tampere university hospital or in Tampere university.
Pirkanmaa Hospital District – Anne Kahiluoto16 02.05.23
Schedule
Phase I-II Research Center 1/2015 Extension 1/2016